TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

F. Demichelis; K. Fall; S. Perner; O. Andrén; F. Schmidt; S. R. Setlur; Y. Hoshida; J. M. Mosquera; Y. Pawitan; C. Lee; H. O. Adami; L. A. Mucci; P. W. Kantoff; S. O. Andersson; A. M. Chinnaiyan; J. E. Johansson; M. A. Rubin

doi:10.1038/sj.onc.1210237

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

F. Demichelis, K. Fall, S. Perner, O. Andrén, F. Schmidt, S. R. Setlur, Y. Hoshida, J. M. Mosquera, Y. Pawitan, C. Lee, H. O. Adami, L. A. Mucci, P. W. Kantoff, S. O. Andersson, A. M. Chinnaiyan, J. E. Johansson, M. A. Rubin^*

^*Corresponding author for this work

Institute of Pathology

572 Citations (Scopus)

Abstract

The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

Original language	English
Journal	Oncogene
Volume	26
Issue number	31
Pages (from-to)	4596-4599
Number of pages	4
ISSN	0950-9232
DOIs	https://doi.org/10.1038/sj.onc.1210237
Publication status	Published - 05.07.2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/sj.onc.1210237

Cite this

Demichelis, F., Fall, K., Perner, S., Andrén, O., Schmidt, F., Setlur, S. R., Hoshida, Y., Mosquera, J. M., Pawitan, Y., Lee, C., Adami, H. O., Mucci, L. A., Kantoff, P. W., Andersson, S. O., Chinnaiyan, A. M., Johansson, J. E., & Rubin, M. A. (2007). TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene, 26(31), 4596-4599. https://doi.org/10.1038/sj.onc.1210237

@article{0a56fb40c5d74e08a2927046f0f99322,

title = "TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort",

abstract = "The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50\% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15\% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95\% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.",

author = "F. Demichelis and K. Fall and S. Perner and O. Andr{\'e}n and F. Schmidt and Setlur, \{S. R.\} and Y. Hoshida and Mosquera, \{J. M.\} and Y. Pawitan and C. Lee and Adami, \{H. O.\} and Mucci, \{L. A.\} and Kantoff, \{P. W.\} and Andersson, \{S. O.\} and Chinnaiyan, \{A. M.\} and Johansson, \{J. E.\} and Rubin, \{M. A.\}",

year = "2007",

month = jul,

day = "5",

doi = "10.1038/sj.onc.1210237",

language = "English",

volume = "26",

pages = "4596--4599",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "31",

}

Demichelis, F, Fall, K, Perner, S, Andrén, O, Schmidt, F, Setlur, SR, Hoshida, Y, Mosquera, JM, Pawitan, Y, Lee, C, Adami, HO, Mucci, LA, Kantoff, PW, Andersson, SO, Chinnaiyan, AM, Johansson, JE & Rubin, MA 2007, 'TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort', Oncogene, vol. 26, no. 31, pp. 4596-4599. https://doi.org/10.1038/sj.onc.1210237

TY - JOUR

T1 - TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

AU - Demichelis, F.

AU - Fall, K.

AU - Perner, S.

AU - Andrén, O.

AU - Schmidt, F.

AU - Setlur, S. R.

AU - Hoshida, Y.

AU - Mosquera, J. M.

AU - Pawitan, Y.

AU - Lee, C.

AU - Adami, H. O.

AU - Mucci, L. A.

AU - Kantoff, P. W.

AU - Andersson, S. O.

AU - Chinnaiyan, A. M.

AU - Johansson, J. E.

AU - Rubin, M. A.

PY - 2007/7/5

Y1 - 2007/7/5

N2 - The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

AB - The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high estrogen-regulated gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

UR - https://www.scopus.com/pages/publications/34248510706

U2 - 10.1038/sj.onc.1210237

DO - 10.1038/sj.onc.1210237

M3 - Journal articles

C2 - 17237811

AN - SCOPUS:34248510706

SN - 0950-9232

VL - 26

SP - 4596

EP - 4599

JO - Oncogene

JF - Oncogene

IS - 31

ER -

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this